Ribonuclease 4 is associated with aggressiveness and progression of prostate cancer.

Abstract

Prostate specific antigen screening has resulted in a decrease in prostate cancer-related deaths. However, it also has led to over-treatment affecting the quality of life of many patients. New biomarkers are needed to distinguish prostate cancer from benign prostate hyperplasia (BPH) and to predict aggressiveness of the disease. Here, we report that ribonuclease 4 (RNASE4) serves as such a biomarker as well as a therapeutic target. RNASE4 protein level in the plasma is elevated in prostate cancer patients and is positively correlated with disease stage, grade, and Gleason score. Plasma RNASE4 level can be used to predict biopsy outcome and to enhance diagnosis accuracy. RNASE4 protein in prostate cancer tissues is enhanced and can differentiate prostate cancer and BPH. RNASE4 stimulates prostate cancer cell proliferation, induces tumor angiogenesis, and activates receptor tyrosine kinase AXL as well as AKT and S6K. An RNASE4-specific monoclonal antibody inhibits the growth of xenograft human prostate cancer cell tumors in athymic mice.

• Authors: Nil Vanli, Jinghao Sheng, Shuping Li, Zhengping Xu, Guo-Fu Hu
• Journal: Communications biology (Commun Biol) Vol. 5 Issue 1 Pg. 625 (06 25 2022) ISSN: 2399-3642 [Electronic] England
• PMID: 35752711 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
• Copyright: © 2022. The Author(s).

Chemical References

• Ribonucleases
• ribonuclease 4

Topics

• Animals
• Humans
• Male
• Mice
• Neoplasm Grading
• Prostatic Hyperplasia
• Prostatic Neoplasms (pathology)
• Quality of Life
• Ribonucleases